Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
https://www.zacks.com/stock/news/2208771/want-better-returns-don-t-ignore-these-2-medical-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2208771
Jan 11, 2024 - Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
0
AbbVie (ABBV) Now Trades Above Golden Cross: Time to Buy?
https://www.zacks.com/stock/news/2207004/abbvie-abbv-now-trades-above-golden-cross-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|golden_crossover-2207004
Jan 08, 2024 - Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
0
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
https://www.zacks.com/stock/news/2206449/will-abbvie-abbv-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2206449
Jan 05, 2024 - AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363
Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
0
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2205271/abbvie-abbv-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2205271
Jan 03, 2024 - AbbVie (ABBV) closed the most recent trading day at $160.46, moving +0.4% from the previous trading session.
0
1 Concerning Trend for AbbVie Investors to Keep an Eye On
https://www.fool.com/investing/2024/01/03/1-concerning-trend-for-abbvie-investors-to-keep-an/?source=iedfolrf0000001
Jan 03, 2024 - Is AbbVie a good stock for dividend investors to own?
0
2 Biotech Stocks You Can Buy and Hold for the Next Decade
https://www.fool.com/investing/2024/01/02/2-biotech-stocks-you-can-buy-and-hold-for-the-next/?source=iedfolrf0000001
Jan 02, 2024 - The types of innovative drugs these companies develop are always in high demand.
0
Here's How Much a $1000 Investment in AbbVie Made 10 Years Ago Would Be Worth Today
https://www.zacks.com/stock/news/2204045/here-s-how-much-a-1000-investment-in-abbvie-made-10-years-ago-would-be-worth-today?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2204045
Jan 01, 2024 - Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
0
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-1-2-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202697
Dec 27, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
0
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201667
Dec 22, 2023 - Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
0